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Summary
Background We aimed to assess whether interferon-γ release assays (IGRAs) can predict the development of active 
tuberculosis and whether the predictive ability of these tests is better than that of the tuberculin skin test (TST).
Methods Longitudinal studies of the predictive value for active tuberculosis of in-house or commercial IGRAs were 
identiﬁ ed through searches of PubMed, Embase, Biosis, and Web of Science and complementary manual searches up 
to June 30, 2011. Eligible studies included adults or children, with or without HIV, who were free of active tuberculosis 
at study baseline. We summarised incidence rates in forest plots and pooled data with random-eﬀ ects models when 
appropriate. We calculated incidence rate ratios (IRR) for rates of disease progression in IGRA-positive versus 
IGRA-negative individuals.
Findings 15 studies had a combined sample size of 26 680 participants. Incidence of tuberculosis during a median 
follow-up of 4 years (IQR 2–6), even in IGRA-positive individuals, was 4–48 cases per 1000 person-years. Seven studies 
with no possibility of incorporation bias and reporting baseline stratiﬁ cation on the basis of IGRA results showed a 
moderate association between positive results and subsequent tuberculosis (pooled unadjusted IRR 2·10, 95% CI 
1·42–3·08). Compared with test-negative results, IGRA-positive and TST-positive results were much the same with 
regard to the risk of tuberculosis (pooled IRR in the ﬁ ve studies that used both was 2·11 [95% CI 1·29–3·46] for IGRA 
vs 1·60 [0·94–2·72] for TST at the 10 mm cutoﬀ ). However, the proportion of IGRA-positive individuals in seven of 
11 studies that assessed both IGRAs and TST was generally lower than TST-positive individuals. 
Interpretation Neither IGRAs nor the TST have high accuracy for the prediction of active tuberculosis, although use of 
IGRAs in some populations might reduce the number of people considered for preventive treatment. Until more predictive 
biomarkers are identiﬁ ed, existing tests for latent tuberculosis infection should be chosen on the basis of relative speciﬁ city 
in diﬀ erent populations, logistics, cost, and patients’ preferences rather than on predictive ability alone. 
Funding Special Programme for Research and Training in Tropical Diseases (WHO), Wellcome Trust, Canadian 
Institutes of Health Research, UK Medical Research Council, and the European and Developing Countries Clinical 
Trials Partnership.
Introduction
A third of the world’s population is estimated to be 
infected with Mycobacterium tuberculosis,1 providing a 
very large reservoir for future active tuberculosis. The 
tuberculin skin test (TST) has traditionally been used to 
identify people with latent M tuberculosis infection who 
will beneﬁ t from isoniazid preventive treatment.2 Despite 
its usefulness and simplicity, the TST has limitations—
its speciﬁ city is aﬀ ected by BCG vaccination and its 
predictive value for incident tuberculosis disease is low.
T-cell-based interferon-γ release assays (IGRAs) can 
also be used for the diagnosis of M tuberculosis infection, 
and have been available for the past decade. Two licensed 
IGRAs are commercially available: QuantiFERON TB 
Gold in tube (Cellestis, Carnegie, Victoria, Australia) and 
T-SPOT.TB (Oxford Immunotec, Abingdon, UK). Studies 
of these assays have been reviewed for their ability to 
identify latent infection and to diagnose active disease in 
various populations.3–7 IGRAs, like the TST, are a 
surrogate marker for M tuberculosis infection, indicating 
a cellular immune response to recent or remote 
sensitisation. However, neither assay can distinguish 
between latent and active tuberculosis.8 Nevertheless, use 
of IGRAs in tuberculosis programmes is encouraged in 
many countries with low or intermediate incidence.9 
The clinical beneﬁ t of IGRAs can be proven only if 
individuals identiﬁ ed as having latent tuberculosis 
infection by IGRA are at increased risk of active 
tuberculosis compared with test-negative individuals and 
if these individuals beneﬁ t substantially from preventive 
treatment. TST positivity is a surrogate marker for risk of 
subsequent tuberculosis (with those testing positive 
having a relative risk of about 2), and TST-positive 
individuals beneﬁ t from isoniazid preventive treat-
ment.2,10–15 To show equivalent or superior clinical value to 
TSTs, IGRAs should be assessed in various at-risk sub-
groups. Such longitudinal data are emerging, but have 
not been systematically reviewed. 
We previously published systematic and narrative 
reviews on IGRA accuracy and performance in various 
subgroups.4–8 We did a systematic review and subsequent 
meta-analysis to assess whether IGRAs can prospectively 
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predict the development of active tuberculosis in 
individuals without active disease at baseline and 
whether that predictive ability is higher than that of the 
TST. Our secondary objectives were to compare rates of 
tuberculosis in IGRA-positive individuals with TST-
negative or TST-positive results who received isoniazid 
preventive treatment, to assess the eﬀ ect of 
immunological pheno types of discordant-concordant 
TST and IGRA results at baseline on subsequent 
tuberculosis rates, to establish whether a gradient 
association exists between quantitative interferon-γ 
response and rates of progression to tuberculosis 
disease, and to assess estimates of false-positive or false-
negative IGRA results versus TST results. 
Methods
Search strategy and study selection
We updated the database searches (with the same terms) 
that were done in previous systematic reviews4–8 and 
searched PubMed, Embase, Biosis, and Web of Science 
for relevant IGRA studies (up to June 30, 2011) that 
reported data on IGRA predictive value in all settings. We 
reviewed citations of all original articles published in all 
languages. In addition to electronic database searches, 
we reviewed bibliographies of previous reviews and 
guidelines on IGRA and screened the citations of relevant 
original articles. We contacted experts to obtain relevant 
citations. No language restrictions were made and full-
length papers, conference proceedings, and abstracts 
were included. When necessary, we contacted authors of 
primary studies to obtain additional information.
Studies were eligible for inclusion if they were 
longitudinal studies of adults or children, with or 
without HIV, who were free of active disease at study 
baseline that speciﬁ cally stated assessment of the 
predictive ability of IGRA as a primary objective, had 
any longitudinal study design (eg, prospective or 
retrospective cohort) in any setting (low-income, 
middle-income, or high-income country), and described 
either active or passive follow-up of patients for any 
duration. Index tests assessed were any IGRA for 
M tuberculosis infection (whole-blood ELISA, enzyme-
linked immunosorbent spot [ELISPOT], in-house 
laboratory-developed non-commercial assay, or the 
latest generation of commercially licensed assays) that 
included at least one region of diﬀ erence 1 (RD1) 
antigen (eg, early secretory antigenic target 6 [ESAT6], 
culture ﬁ ltrate protein 10 [CFP10], Rv2654c [antigen 
TB7.7]). The study endpoint assessed was active 
tuberculosis caused by M tuberculosis (we did not 
include studies that assessed non-tuberculous 
mycobacterium diseases), and the reference standard 
for the endpoint was any diagnosed incident active 
tuberculosis. Studies were included even if they did not 
stratify results into culture-conﬁ rmed tuberculosis and 
clinically diagnosed tuberculosis.
Data extraction
Two reviewers (MXR and MP) independently assessed 
eligible articles for inclusion; disagreements were 
resolved by consensus. All articles included were assessed 
by a reviewer (MXR), who also extracted data, including 
study design, participants, country, period of recruitment, 
proportion of participant who had received BCG 
vaccination, IGRA methods (assay used, test version, 
cutoﬀ -point used), TST methods (dose of puriﬁ ed protein 
derivative [PPD], cutoﬀ -point used), and outcome data 
(eg, baseline TST and IGRA positivity rates, IGRA or 
TST concordance or discordance, and rates of progression 
to active tuberculosis). DL independently veriﬁ ed the 
extracted data on studies’ general characteristics, test 
characteristics, and main results.
Quality assessment
IGRA predictive value studies are not focused on 
diagnostic test accuracy. We therefore used a modiﬁ ed 
Newcastle-Ottawa quality assessment scale for non-
randomised observational studies16 rather than the 
quality assessment tool for diagnostic accuracy studies.17 
Studies were assessed for selection of study groups, 
comparability of study groups, and ascertainment of 
either the exposure or outcome of interest. Speciﬁ c 
modiﬁ cations were made to the selection and 
ascertainment of outcome items; high quality studies 
were those in which all cases of active tuberculosis were 
microbiologically conﬁ rmed, IGRA results were not 
incorporated into the reference standard (ie, no 
incorporation bias), and clinicians who assessed 
732 records identiﬁed
24 full-text articles assessed for eligibility
708 records excluded 
15 studies included in 
 qualitative synthesis
15 studies included in quantitative synthesis
 (meta-analysis)
 7 studies included for estimation of 
  incident rate ratios
 15 studies included for cumulative 
  incidence risk ratios calculation
9 full-text articles excluded*
 1 was out-of-date41
 2 did not use RD1 antigens42,43
 1 did not have enough information 
  in abstract44
 1 reported no incident tuberculosis 
  recorded during follow-up45
 2 used an old commercial IGRA46,47
 2 had a primary objective other than 
  predictive ability of IGRA48,49
Figure 1: Study selection 
*See webappendix p 4 for further exclusion details.See Online for webappendix
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participants for active tuberculosis were masked to IGRA 
results. Incorporation of index tests and non-blinded 
assessments of possible tuberculosis cases could lead to 
relative risk estimates biased in favour of positive IGRA 
results. IGRA-positive results could instigate tuberculosis 
investigations that might be more extensive than they 
would be for individuals with IGRA-negative results, 
resulting in further diﬀ erential work-up bias 
(webappendix p 3). We did sensitivity analyses to explore 
the eﬀ ect of key quality items on our main results.
Statistical analysis
The main outcome of interest was person-years incidence 
rates of disease (incidence density), stratiﬁ ed by test 
Country 
(income 
status)
Age group 
(years)
Individuals with 
HIV in cohort (%)
Population Individuals 
assessed 
(n)
Individuals followed 
up and included in 
analysis (n)
IPT given (%)* Tuberculosis 
diagnoses 
included
Doherty et al 
(2002)30
Ethiopia (LIC) Adults 
(15–65)
No; exclusion 
criterion
Tuberculosis 
case-contacts
38 24 No Smear and 
culture
Hill et al 
(2008)32
The Gambia 
(LIC)
Adults and 
children
(0·5–100)
Yes (2%) Tuberculosis 
case-contacts
2381 2348 No TST, smear, 
and culture
Bakir et al 
(2008)27
Turkey (MIC) Children 
(0–16)
Not stated Tuberculosis 
case-contacts
1024 908 Yes (76% of 
908)
Smear and 
culture
Aichelburg 
et al (2009)26
Austria (HIC) Adults 
(IQR 31–46)
Yes (100%) Outpatients with 
HIV
834 822 No IGRA and 
culture
Kik et al 
(2009)35
Netherlands 
(HIC)
Adults 
(16–45+)
No; exclusion 
criterion
Tuberculosis 
case-contacts
433 339 No; exclusion Smear and 
culture
Del Corral et al 
(2009)28
Colombia 
(MIC)
Adults and 
children
(IQR 10–42)
Unknown† Tuberculosis  
case-contacts
2060 2060 No Smear and 
culture
Lienhardt et al 
(2010)37
Senegal (LIC) Adults and 
children 
(18–71)
Unknown† Tuberculosis 
case-contacts
2762 2679 Yes (% NS) Smear and 
culture
Yoshiyama 
et al (2010)39
Japan (HIC) Adults and 
children
(0–60+)
Unknown† Tuberculosis 
case-contacts 
(retrospective)
NS 5676 Yes (20% of 
3102)
IGRA‡
Leung et al 
(2010)36
China (MIC) Adults 
(mean 60)
Unknown† Outpatients with 
silicosis
331 308 Yes (33% of 
203)
Smear and 
culture
Harstad et al 
(2010)31
Norway (HIC) Adults 
(18–50+)
Unknown† Asylum seekers NS 823 Yes (3%) IGRA‡
Diel et al 
(2010)29
Germany 
(HIC)
Adults and 
children 
(1–62)
No; exclusion 
criterion
Tuberculosis 
case-contacts 
1417 1335 Yes (% NS) TST, IGRA, and 
culture
Jonnalagadda 
et al (2010)33
Kenya (LIC) Adults 
(24–26)
Yes (100%) HIV cohort with 
no prior 
tuberculosis 
(retrospective) 
333 258 No Self-reported
Jonnalagadda 
et al (2010)33§
Kenya (LIC) Infants (<1) Unknown HIV-exposed 
infants 
(retrospective)
327 250 No Report by the 
mother
Joshi et al 
(2011)34
India (MIC) Adults 
(18–40)
Unknown Health-care 
workers with no 
prior tuberculosis 
(retrospective)
726 719 Yes (17% of 
360)
Self-reports 
(conﬁ rmed)
Mahomed 
et al (2011)38
South Africa 
(MIC)
Adolescents 
(12–18)
Unknown Individuals with 
no prior 
tuberculosis
6363 5244 No TST, IGRA, 
smear, and 
culture
Costa et al 
(2011)40
Portugal 
(HIC)
Adults 
(<25–50+)
No Health-care 
workers
2889 2876 Yes (2% of 
2876)
TST, IGRA, and 
culture
HIC=high-income country. IGRA=interferon-γ release assay. IPT=isoniazid preventive treatment. LIC=low-income country. MIC=middle-income country. NS=not stated. 
TST=tuberculin skin test. The proportion of participants who completed follow-up was more than 80% for all studies except for those done in Norway31 (cannot estimate), Japan39 
(55%) and Germany29 (70%)—follow-up rates were not reported in the studies done in Netherlands35 and Norway.31 *Bakir et al27 IPT given on the basis of age and positive skin 
tests; Aichelburg et al26 all eligible participants refused; Yoshiyama et al39 criteria were non-random and non-standard; Leung et al36 given on the basis of TST positivity; Harstad et 
al31 and Diel et al29 given if IGRA positive; Joshi et al34 given if TST or IGRA positive; and Costa et al40 given to those who had conversion in past 2 years from negative to positive on 
TST, IGRA, or both, as conﬁ rmed by study investigators. †HIV prevalence unknown but likely to be low, except for the Norwegian cohort where prevalence is probably high. 
‡Conﬁ rmed in personal communication with investigators. §Additional information requested from the authors.
Table 1: Study characteristics of subpopulations included
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results. We calculated incidence rate ratios (IRR) for rates 
of disease progression in IGRA-positive versus 
IGRA-negative individuals (we did the same for 
TST-positive vs TST-negative individuals). We also 
calculated risk ratios (cumulative incidence ratios) 
because several studies did not report rates or provide 
adequate information to allow computation of rates. We 
calculated DerSimonian and Laird random-eﬀ ects pooled 
relative risks with 95% CIs;18 0·5 was added to correct for 
zero values in two by two tables.19 
Because confounding is a concern in observational 
studies, we assessed whether adjusted IRR estimates 
were diﬀ erent from unadjusted estimates. We had 
planned to use the best-reported adjusted estimate of 
relative risk from each study if diﬀ erent from unadjusted 
estimates. However, most studies did not report adjusted 
estimates, and for those studies that did multivariable 
analyses, adjusted estimates were much the same as 
unadjusted estimates. Therefore, we used unadjusted 
estimates. Except when clearly indicated, all assays in 
the analyses were presented as IGRA irrespective of 
whether they were whole-blood ELISA or ELISPOT, in-
house or commercial. 
Heterogeneity was assessed with the I² statistic and 
deﬁ ned as low (I²≤25%), moderate (25%<I²≤50%), or 
high (I²>50%).20,21 We did not report pooled estimate 
measures or interpreted them cautiously when the I² 
value was greater than 25%. When heterogeneity was 
identiﬁ ed, reasons were explored by calculation of eﬀ ect 
measures stratiﬁ ed by three prespeciﬁ ed subgroups: key 
study quality items, country-level stratiﬁ cations, and 
study-level stratiﬁ cations. Country-level stratiﬁ cations 
were high-income versus low-income or middle-
income,22 estimated tuberculosis incidence per 
100 000 individuals, and HIV prevalence. Study-level 
stratiﬁ cations were study population or cohort followed, 
retrospective or prospective design, proportion of 
participants with BCG scar, age strata (adult or children), 
inclusion of individuals with HIV, provision of isoniazid 
preventive treatment to individuals in the study, whole-
blood ELISA versus ELISPOT assay, in-house or 
commercial assay, assay incubation period, and TST 
status of participants.
Diagnostic accuracy estimates for progression to 
disease were chosen as surrogates for patient-relevant 
outcomes.23 A false-positive test result could result in 
unnecessary treatment in an individual who would not 
have progressed to tuberculosis disease, whereas a false-
negative result would mean progression to active 
tuberculosis disease that could have been prevented. 
Type of IGRA (in-house or commercial); M tuberculosis antigens 
or peptides* 
IGRA cutoﬀ † TST cutoﬀ (s) Blinding to 
IGRA results
Doherty et al (2002)30 WBA, ELISA (in house); PPD, ESAT 6 100 pg/mL ·· Yes
Hill et al (2008)32 ELISPOT (in house); ESAT6, CFP-10 ~32 SFC ≥10 mm ‡NS
Bakir et al (2008)27 ELISPOT (in house); ESAT6, CFP-10 ~20 SFC ≥5 mm Yes
Aichelburg et al (2009)26 WBA, ELISA (QFT-Gold in tube); ESAT6; CFP-10, Rv2654c (p38–55) ≥0·35 IU/mL ·· No
Kik et al (2009)35 ELISPOT (T-SPOT.TB); ESAT6, CFP-10 ≥8 SFU after negative well 
subtraction (~20 SFC) 
(inclusion criterion) NS
Kik et al (2009)35 WBA, ELISA (QFT-Gold in tube); ESAT6, CFP-10, Rv2654c (p38–55) ≥0·35 IU/ml (~14 pg/mL)   
Del Corral et al (2009)28 WBA, ELISA (in house); CFP-10, CFP, Ag85A, Rv2031c 22 pg/mL ≥10 mm and 
≥5 mm
‡NS
Lienhardt et al (2010)37 ELISPOT (in house); ESAT6, CFP-10 ≥20 SFC after negative well 
subtraction and ≥32 SFC
≥10 mm Yes
Yoshiyama et al (2010)39 WBA, ELISA (QFT-Gold in tube); ESAT6, CFP-10, Rv2654c (p38–55) ≥0·35 IU/mL (~14 pg/mL) ·· No
Leung et al (2010)36 ELISPOT (T SPOT-TB); ESAT6, CFP-10 ≥6 SFU (~20 SFC) ≥5 mm, ≥10 mm, 
and ≥15 mm 
Yes
Harstad et al (2010)31 WBA, ELISA (QFT-Gold in tube); ESAT6, CFP-10, Rv2654c (p38–55) ≥0·35 IU/mL ( ~14 pg/mL) (inclusion criterion) No
Diel et al (2010)29 WBA, ELISA (QFT-Gold in tube); ESAT6, CFP-10, Rv2654c (p38–55) ≥0·35 IU/mL ( ~14 pg/mL) ≥5 mm, ≥10 mm No
Jonnalagadda et al (2010)33 ELISPOT (T.SPOT.TB); ESAT6, CFP-10 ≥6 SFU (~20 SFC) ·· Yes
Joshi et al (2011)34 WBA, ELISA (QFT-Gold in tube); ESAT6, CFP-10, Rv2654c (p38–55) ≥0·35 IU/mL (~14 pg/mL) ≥10 mm §Yes
Mahomed et al (2011)38 WBA, ELISA (QFT-Gold in tube); ESAT6, CFP-10, Rv2654c (p38–55) ≥0·35 IU/mL (~14 pg/mL) ≥10 mm No
Costa et al (2011)40 WBA, ELISA (QFT-Gold in tube); ESAT6, CFP-10, Rv2654c (p38–55) ≥0·35 IU/mL (~14 pg/mL) ≥0 mm ¶No
CFP=culture ﬁ ltrate protein. ESAT=early secreted antigenic target. HIC=high-income country. LIC=low-income country, MIC=middle-income country, NS=not stated. 
TST=tuberculin skin test. PPD=puriﬁ ed protein derivative. WBA=whole-blood assay. *All measured interferon-gamma. Studies done in Turkey,27 Colombia,28 and South 
Africa38 described serial testing: interferon-γ release assay (IGRA) repeated at 6 months of follow-up, at 2 months of follow-up, and repeated for individuals with suspected 
tuberculosis, respectively. †Unit conversions given are equivalent to cutoﬀ s deﬁ ned in original papers: Hill et al32 (positive well with eight spot-forming units [SFU]> negative 
well; one pool of overlapping peptides must be positive); Bakir et al27 (≥5 mean spot-forming cells [SFC] in duplicate wells than negative wells and if number of SFCs was twice 
the mean of negative control wells). Incubation time was more than 24 h in the studies done in Ethiopia (120 h) and Colombia (168 h). ‡Although not reported, study 
investigators conﬁ rmed that clinicians were blinded to IGRA results. §Cases were not diagnosed by researchers, but health-care workers were aware of IGRA results. 
¶Clinicians were not blinded to IGRA-positive results. 
Table 2: Test characteristics
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Bivariate random-eﬀ ects regression was done to obtain 
global summaries of sensitivity and speciﬁ city separately 
for studies that did IGRA (whole-blood ELISA or 
ELISPOT) and TST. We used Stata (version 10/MP) for 
all analyses.24
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. MXR and MP had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Figure 1 shows the study selection process, reported 
according to PRISMA guidelines.25 15 studies met our 
inclusion criteria (ﬁ gure 1);26–40 results of one study were 
described in two reports.29,41 Of the 15 included studies, 
four were done in low-income countries, ﬁ ve in middle-
income countries, and six in high-income countries; 
three had retrospective cohorts (table 1). The 15 included 
studies had a combined cohort size of 26 680 participants, 
with the study in South Africa38 being the largest as of 
June 30, 2011 (11 988 person-years of follow-up).
All study cohorts were at high risk of tuberculosis 
(table 1). Two studies26,33 followed up individuals with HIV 
(one of which, the study by Jonnalagadda and colleagues,33 
also studied infants who were followed up; main outcome 
results were stratiﬁ ed into mothers and infants when 
possible), one36 followed up a group of patients with 
silicosis, one31 followed-up a cohort of asylum seekers, 
two34,40 followed up cohorts of health-care workers, one 
study38 followed up adolescents in a high-incidence area, 
and eight27–29,30,32,35,37,39 followed up case contacts (table 1). 
All studies in high-income countries used data collected 
during routine care of patients. TST positivity was a 
prerequisite for IGRA testing in the studies by Kik and 
colleagues35 and Harstad and colleagues.31
Median study duration was 3 years (IQR 2–5). In three 
studies,29,31,39 more than 20% of the cohort was lost to 
follow-up. In one study,29 276 (72%) of 381 lost to follow-
up were IGRA negative and had no information about 
development of tuberculosis. 0–76% of participants 
received isoniazid preventive treatment, which was 
not given to test-positive individuals in eight 
studies.26,28,30,32,33,35,38,40
Ten of 15 studies did a whole-blood ELISA, two of 
which28,30 used in-house assays and eight26,29,31,34,35,38–40 used 
the third-generation QuantiFERON-TB Gold in tube 
technology (table 2). Six studies assessed the ELISPOT 
assay—three used in-house assays27,32,37 and three used 
T-SPOT.TB.33,35,36 All studies used incubation periods of 
less than 24 h, except for Doherty and colleagues30 (5 days) 
and del Corral and colleagues (7 days).28 11 of 15 studies 
included TST,27,29,31,32,34,35–38,40 but only eight27,29,32,34,36–38,40 
reported results of the predictive value of TST 
(webappendix p 8).
Table 3 shows key quality characteristics of included 
studies. Individuals selected seemed to be representative 
of speciﬁ c high-risk groups of interest within the 
population (eg, case contacts or health-care workers); both 
IGRA-positive and IGRA-negative individuals came from 
the same high-risk for progression groups. However, 
studies varied in quality, especially with respect to 
ascertainment of incident tuberculosis and the potential 
for incorporation and diﬀ erential work-up biases. Only in 
eight studies29,34–40 were at least half the active tuberculosis 
cases microbiologically conﬁ rmed (webappendix p 5). In 
seven studies,26,29,31,35,38–40 positive IGRA results were 
incorporated in the case deﬁ nitions of active tuberculosis. 
Thus, IGRA-positive individuals were more likely than 
were IGRA-negative individuals to be investigated for 
tuberculosis or diagnosed with tuberculosis.
Nine studies27,28,32–38,45 reported incidence rates per 
person-time of follow-up (all of which except Kik and 
colleagues35 reported rates stratiﬁ ed by IGRA status), the 
remaining six reported cumulative incidence risk 
Low or 
intermediate 
income (n=9)
High 
income 
(n=6)
Selection
Representative sample 9 6
IGRA positive and negative from same source population 9 6
Assay described in detail 9 6
Active tuberculosis excluded at baseline* 8 4
Methods include smear and culture† ·· ··
Whole or random sample screened for tuberculosis 0 0
IGRA incorporated into reference standard (or not reported)‡ 2 6
Comparability
Adjustment of identiﬁ ed confounders‡ 3 1
Outcome
Blind assessment and active follow-up by regular visits to the clinic or home to 
check for tuberculosis§
5 0
IGRA incorporated into reference standard (or not reported)¶ 1 6
>50% incident cases culture-conﬁ rmed|| 4 4
Study follow-up at least 1 year 9 6
≥80% of cohort followed up** 9 4
Outcome reported as incidence rate and rate ratio (person-time incidence)†† 8 1
*Studies in Germany,29 Japan,39 Kenya,33 and Norway31 did not clearly report whether active tuberculosis was 
adequately excluded at baseline. †Not assessed—studies reported that participants were screened for tuberculosis 
symptoms and signs, and that only those with a positive screen were investigated further for tuberculosis with 
methods that may or may not have included smear, culture, or both. ‡Incorporation bias (Austria,26 Japan,39 Norway,31 
Germany,29 India,34 South Africa,38 Portugal40) and not reported (Netherlands35). ‡No or poor adjustment of 
confounders (Ethiopia,30 The Gambia,32 Turkey [isoniazid preventive treatment only],27 Austria,26 Colombia,28 Norway,31 
Kenya,33 India,34 and South Africa38). §For ascertainment of any health complaint that could have been active 
tuberculosis: Turkey,37 China,36 Colombia (home visits),28 Senegal (home visits),37 and The Gambia22 (home visits). 
Studies without active follow-up include the studies done in Kenya33 and India,34 which relied on self-reports, 
tuberculosis subsequently conﬁ rmed for nine of 14 in the Indian study. ¶Incorporation bias (Austria, Japan, Norway, 
Germany, South Africa, Portugal) and not reported (Netherlands). ||More than 50% cases culture-conﬁ rmed 
(Senegal,37 China, Netherlands, Japan, Germany, South Africa, India, and Portugal). **Inadequate follow-up of cohort 
or poor description for three high-income countries—Japan (55%), Norway (cannot estimate), Germany (70%, about 
70% of whom were IGRA negative). ††Cumulative incidence and risk ratios reported (Ethiopia, and all six studies done 
in high-income countries). 
Table 3: Summary of study quality (modiﬁ ed Newcastle-Ottawa scale items)
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(webappendix p 5). Tuberculosis rates in IGRA-positive 
individuals were 4–48 cases per 1000 person-years, 
whereas rates in IGRA-negative individuals were 
2–24 cases per 1000 person-years during a median period 
of observation of 4 years (IQR 2–6; ﬁ gure 2).33,34 None of 
the studies reported rates of tuberculosis in IGRA-
positive individuals, with both TST-negative and TST-
positive results, who were given preventive treatment.
We compared unadjusted cumulative incidence risk 
ratios (RR) estimates because adjusted estimates were 
not available for most studies. The pooled RR for IGRA-
positive results was 3·54 (95% CI 2·23–5·60), but 
heterogeneity was high (ﬁ gure 3). 
Stratiﬁ cation of studies by whether incorporation bias 
or diﬀ erential work-up bias were or were not possible 
yielded a subgroup RR in the possibly biased studies 
higher than that in the subgroup of those in which such 
bias was not possible (ﬁ gure 3). Studies with possible 
incorporation or diﬀ erential work-up bias were therefore 
omitted from the rest of the review’s main outcomes.
Although we had planned to explore heterogeneity by 
study characteristics, after exclusion of studies with 
possible incorporation or diﬀ erential work-up biases, 
which included all those from high-income countries 
and with low national tuberculosis incidence, we were 
left with eight studies,27,28,30,32–34,36,37 all from low-income or 
middle-income countries. For these studies, we detected 
no statistical diﬀ erence across strata for country-level 
subgroups (World Bank income classiﬁ cation, 
tuberculosis case-detection rate, and HIV prevalence) or 
study-level subgroups (tuberculosis case contacts vs other 
cohorts, prospective vs retrospective study, BCG scar, 
children vs adults, any individuals with HIV in cohort, 
any isoniazid preventive treatment given, whole-blood 
ELISA vs ELISPOT assay, in-house vs commercial assay, 
and assay incubation period; data not shown).
In seven studies27,28,32–34,36,37 reporting tuberculosis 
incidence rates stratiﬁ ed by IGRA status, individuals 
with positive IGRA results at baseline had a higher 
incidence of active tuberculosis than did those with 
negative results (n=9530; ﬁ gure 4). For three studies,34,36,37 
the pooled IRR in microbiologically conﬁ rmed 
tuberculosis cases was higher (3·5, 95% CI 1·3–10·0) 
than for all cases of tuberculosis diagnosed (2·2, 1·1–4·5), 
but the diﬀ erence was not signiﬁ cant. In ﬁ ve studies that 
reported results of multivariable analyses,27,32,33,36,37 the 
adjusted IRR were much the same as the crude IRR 
(webappendix p 6). 
Five studies27,32,36–38 without biases in incorporation or 
diﬀ erential work-up stratiﬁ ed tuberculosis incidence by 
IGRA and TST results status at baseline. All studies 
used 0·1 mL of 2TU PPD RT23, but diﬀ erent cutoﬀ s for 
positivity were selected in these studies, according to 
national guidelines. Relative risks were stratiﬁ ed by 
TST cutoﬀ , when possible. The IRR of incident 
tuberculosis in test-positive individuals compared with 
test-negative individuals was slightly higher for IGRA 
than for the TST, but was not signiﬁ cant because of 
overlapping CIs (ﬁ gure 5). 
Assessment of discordant results can help to ﬁ nd out 
whether IGRAs are better than TST in the prediction of 
IGRA positive
Hill et al (2008)32 The Gambia 9·24 (3·80–14·60)
Bakir et al (2008)27 Turkey 20·50 (10·20–36·70)
del Corral et al (2009)28 Colombia 7·70 (5·10–11·30)
Lienhardt et al (2010)37 Senegal 14·40 (8·40–23·00)
Leung et al (2010)36 China 32·00 (17·80–52·30)
Jonnalagadda et al (2010)33 Kenya (mothers) 42·00 (15·00–91·00)
Jonnalagadda et al (2010)33 Kenya (infants) 48·00 (16·00–112·00)
Joshi et al (2011)34 India 3·69 (1·66–8·21)
Mahomed et al (2011)38 South Africa 6·40 (4·50–8·70)
Country Incidence rate (95% CI)
0 25 7550 100 125
IGRA negative
Hill et al (2008)32 The Gambia 5·00 (1·90–8·10)
Bakir et al (2008)27 Turkey 6·00 (1·60–15·40)
del Corral et al (2009)28 Colombia 4·10 (1·70–8·50)
Lienhardt et al (2010)37 Senegal 6·90 (2·50–14·90)
Leung et al (2010)36 China 7·10 (0·90–25·50)
Jonnalagadda et al (2010)33 Kenya (mothers) 16·00 (3·00–47·00)
Jonnalagadda et al (2010)33 Kenya (infants) 24·00 (5·00–69·00)
Joshi et al (2011)34 India 3·38 (1·69–6·76)
Mahomed et al (2011)38 South Africa 2·20 (1·20–3·80)
Figure 2: Unadjusted incidence rates for all tuberculosis diagnoses stratiﬁ ed by interferon-γ release assay 
(IGRA) status 
Incidence rate estimates are per 1000 person-years from individual studies that provided person-time data 
stratiﬁ ed by IGRA status at baseline. 
Possible
Aichelburg et al (2009)26 Austria 136·13 (7·16–2588·46)
Kik et al (2009)35 Netherlands 1·40 (0·34–5·74)
Yoshiyama et al (2010)39 Japan 6·74 (3·63–12·52)
Harstad et al (2010)31 Norway 18·76 (2·36–149·22)
Diel et al (2010)29 Germany 148·36 (9·00–2446·45)
Mahomed et al (2011)38 South Africa 2·89 (1·55–5·41)
Costa et al (2011)40 Portugal 18·38 (0·99–341·04)
Subtotal (l2=70·4%, p=0·003) 8·35 (3·19–21·87)
Overall (I2=56·9%, p=0·003) 3·54 (2·23–5·60)
None
Doherty et al (2002)30 Ethiopia 10·00 (1·42–70·22)
Hill et al (2008)32 The Gambia 1·84 (0·79–4·31)
Bakir et al (2008)27 Turkey 3·80 (1·22–11·86)
del Corral et al (2009)28 Colombia 1·89 (0·83–4·34)
Lienhardt et al (2010)37 Senegal 2·12 (0·85–5·34)
Leung et al (2010)36 China 3·82 (0·89–16·40)
Jonnalagadda et al (2010)33 Kenya (mothers) 2·69 (0·69–10·52)
Jonnalagadda et al (2010)33 Kenya (infants) 2·23 (0·54–9·12)
Joshi et al (2011)34 India 1·09 (0·38–3·10)
Subtotal (l2=0·0%, p=0·658) 2·22 (1·54–3·19)
Country Risk ratio (95% CI)
0·1 1 5·0
Figure 3: Unadjusted cumulative incidence risk ratios for positive versus negative interferon-γ release assay 
(IGRA) results, by possibility of incorporation bias 
One study35 did not report whether tuberculosis diagnoses methods included IGRA and was therefore included 
along with the six studies26,29,31,38–40 in which IGRA formed part of tuberculosis diagnoses methods and, therefore, 
incorporation bias could not be ruled out. Data from Kenya has been stratiﬁ ed into HIV-exposed infants and their 
mothers who had HIV.33 Pooled risk ratio (RR) estimate with Netherlands T-Spot.TB results (rather than 
QuantiFERON Gold in tube): RR=3·61 (95% CI 2·29–5·69), I²=67·4%, p=0·005.
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tuberculosis disease.50 Four studies27,32,34,37 further explored 
rates of tuberculosis in paired concordant and discordant 
TST and IGRA results (table 4). Rates of tuberculosis 
were slightly higher in discordant pairs when IGRA was 
positive than in pairs when TST was the positive test; 
however, the association with incident active tuberculosis 
in the individual studies was weak (table 4). 
With a 7 day whole-blood ELISA, one study28 assessed 
whether an exposure-gradient relation existed between 
baseline quantitative IGRA strata and subsequent rates of 
tuberculosis (webappendix p 7). Rates across the three 
highest strata were much the same and the CIs overlapped 
(incidence of 7 cases per 1000 person-years [95% CI 2·6–
15·2] for 22–99 pg/mL, 6·7 [3·4–11·7] for 100–999 pg/mL, 
and 7·7 [5·1–11·3] for ≥1000 pg/mL); the incidence per 
1000 person-years in the lowest stratum was 4·1 (1·7–8·5).
Three studies27,34,37 assessed whether baseline median 
IGRA responses in individuals who subsequently 
developed tuberculosis were higher than responses in 
those who did not develop tuberculosis but had positive 
tests. In one study,37 median responses were 250 spot-
forming cells (SFC) per million peripheral blood 
mononuclear cells (PBMC) in individuals who 
subsequently developed tuberculosis and 50 SFC per 
million PBMC in those who did not develop tuberculosis 
(p=0·02). By contrast, two studies27,34 noted no diﬀ erences 
in median responses in individuals who developed 
tuberculosis compared with those who did not. 
Findings from seven27,29,31,35,37,38,40 of 11 studies that assessed 
IGRA and TST suggest that the proportion of IGRA-
positive participants who scored positive at the initial 
baseline visit might be lower than in those who were TST-
positive (at investigator-selected cutoﬀ s; webappendix p 9).
For studies that used the ELISPOT assay, the sensitivity 
for developing active tuberculosis was 72% (95% CI 
58–82) and speciﬁ city was 50% (41–58).27,32,36,37 Estimates 
for TST in those same studies were 72% (58–83) and 41% 
(30–54).27,32,36,37 However, estimates for both tests were 
imprecise. On the basis of these estimates, the false-
positive rate for the ELISPOT and TST were much the 
same—50% (95% CI 42–59) for ELISPOT and 59% 
(46–70) for TST (false-positive rate=100–speciﬁ city). False-
negative rates for the two tests were also similar. An 
estimate for studies that used the whole-blood ELISA 
was available from only two studies that were possibly 
not subject to incorporation or work-up bias.28,34 In one 
study,28 which used a 7 day whole-blood ELISA assay, 
sensitivity was 79% (95% CI 61–91) and speciﬁ city was 
34% (32–36), but in the other study,34 which used an assay 
with a shorter incubation, reported sensitivity was 43% 
(18–72) and speciﬁ city was 59% (55–62). 
Discussion
The strength of the association between positive IGRA 
results and development of active tuberculosis in the 
studies identiﬁ ed was weak to moderate, with relative 
risks of about 2–3. The incidence of tuberculosis, even in 
IGRA-positive individuals, was low, suggesting that most 
IGRA-positive individuals did not progress to tuberculosis 
disease during follow-up. This ﬁ nding is similar to that 
for TST in this meta-analysis and in historical studies.14 
Thus, the most important ﬁ nding in this review is that 
no available tests for latent M tuberculosis infection have 
high prognostic value. 
However, in some populations the proportion of 
IGRA-positive individuals might generally be lower than 
the proportion of TST-positive individuals (as shown in 
seven of 11 studies assessed). This occurrence could be 
because of either higher IGRA speciﬁ city for 
M tuberculosis infection or lower sensitivity than with 
TST. Higher speciﬁ city would suggest that even though 
Whole-blood ELISA
del Corral et al (2009)28 Colombia 1·82 (0·80–4·20)
Lienhardt et al (2010)37 Senegal 2·00 (0·84–5·41)
Jonnalagadda et al (2010)33 Kenya (mothers) 2·60 (0·70–10·30)
Jonnalagadda et al (2010)33 Kenya (infants) 2·00 (0·40–13·10)
Joshi et al (2011)34 India 1·09 (0·31–3·58)
Subtotal (l2=0·0%, p=0·910) 1·82 (1·11–2·97)
Overall (I2=0·0%, p=0·876)  2·10 (1·42–3·08)
ELISPOT
Hill et al (2008)32 The Gambia 1·90 (0·80–4·50)
Bakir et al (2008)27 Turkey 3·41 (1·08–10·70)
Leung et al (2010)36 China 4·50 (1·03–19·68)
Subtotal (l2=0·0%, p=0·535) 2·64 (1·41–4·93)
Country Incidence rate ratio
(95% CI)
0·3 1 20
Figure 4: Unadjusted incidence rate ratios for positive versus negative interferon-γ release assay results, by 
type of assay
TST (10)
Hill et al (2008)32 The Gambia 2·10 (0·89–5·11)
Lienhardt et al (2010)37 Senegal 1·40 (0·48–4·74)
Leung et al (2010)36 China 1·64 (0·53–5·02)
Joshi et al (2011)34 India 1·05 (0·30–3·48)
Subtotal (l2=0·0%, p=0·830) 1·60 (0·94–2·72)
IGRA
Hill et al (2008)32 The Gambia 1·90 (0·80–4·50)
Bakir et al (2008)27 Turkey 3·41 (1·08–10·70)
Lienhardt et al (2010)37 Senegal 1·81 (0·66–5·70)
Leung et al (2010)36 China 4·50 (1·03–19·68)
Joshi et al (2011)34 India 1·09 (0·31–3·58)
Subtotal (l2=0·0%, p=0·568) 2·11 (1·29–3·46)
TST (5)
Bakir et al (2008)27 Turkey 2·65 (0·72–14·62)
Lienhardt et al (2010)37 Senegal 1·26 (0·37–4·29)
Leung et al (2010)36 China 1·03 (0·33–3·15)
Joshi et al (2011)34 India 1·64 (0·47–7·16)
Subtotal (l2=0·0%, p=0·789) 1·43 (0·75–2·72)
Country Incidence rate ratio 
(95% CI)
0·2 1 20
Figure 5: Unadjusted incidence rate ratios for positive versus negative test result, by test type 
 Tuberculin skin test (TST) is stratiﬁ ed by cutoﬀ  for studies that provided values in the original paper or on request. 
TST (10)=TST more than 10 mm. TST (5)=TST more than 5 mm. 
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use of both TST and IGRA is imperfect for informing a 
decision about who should receive preventive treatment, 
the number of individuals identiﬁ ed for preventive 
treatment could be less with IGRA than with TST 
because fewer people are IGRA-positive than are TST-
positive. This characteristic of IGRAs might be useful in 
settings where TST speciﬁ city is compromised by cross-
reactivity with environmental mycobacteria, BCG 
vaccination after infancy, or multiple BCG vaccinations.51 
In such settings, TST-positive and IGRA-negative 
discordance is likely to be common. As noted by 
Zwerling and colleagues,5 high reversion rates of IGRA 
are common in settings with both low and high 
tuberculosis incidence, which might contribute to the 
low proportion of IGRA positivity (compared with TST) 
in many studies. 
We had planned to explore heterogeneity by study 
characteristics. However, stratiﬁ cation by studies with 
possible incorporation or diﬀ erential work-up biases, left 
us with eight studies with a statistically homogeneous 
pooled estimate. Further assessment of these remaining 
studies did not show any statistically signiﬁ cant 
diﬀ erences across subgroup strata. Studies that use 
routine care data, from mostly high-income countries 
where commercial IGRA are already included in 
tuberculosis guidelines, are likely to report results that 
are in favour of IGRA. Although assessment of the tests 
in routine practice should be encouraged, the potential 
issues of incorporation bias or diﬀ erential work-up 
should be anticipated early and be mitigated either in 
study design or at analysis. In the excluded studies, 
incorporation bias would have been mitigated if a deﬁ nite 
diagnosis of incident tuberculosis was made for all cases 
on the basis of microbiological methods instead of 
diagnoses that relied on subjective clinical interpretation 
(unblinded to IGRA results). Complete and identical 
diagnostic work-up of all participants who entered follow-
up, index-test positive and negative, would mitigate 
diﬀ erential work-up bias.52
Overall, most of the studies did not fully answer the 
question of whether IGRA, as a surrogate marker for 
future risk, can predict subsequent active tuberculosis. 
They merely showed a slight positive association between 
initial positive IGRA results and subsequent tuberculosis. 
Most studies were likely to yield exaggerated results in 
favour of a positive association largely because of 
ascertainment bias of active tuberculosis and by not fully 
accounting for other risk factors for tuberculosis. 
Furthermore, no studies assessed the ability of IGRA to 
adequately discriminate and therefore predict individuals 
at risk of developing disease from those not at risk. 
Discriminatory ability, rather than association, is of primary 
interest in predictive studies of disease. One measure of 
association does not imply that the new test can accurately 
discriminate individuals at risk of disease and those who 
will not develop disease.53–56 This fact is widely acknowledged 
in biomarker studies related to cancer and cardiovascular 
epidemiology.56–58 Perfect discrimination will occur only 
when the distribution curves of the marker in individuals 
with disease versus individuals without disease do not 
overlap.56 One marker or test has to be strongly associated 
with disease to be useful for disease prediction.53,56–58 A 
possible reason could be that even strongly associated risk 
factors or markers (eg, TST or IGRA) can perform poorly 
as tests of disease prediction if little variation exists in 
exposure (eg, high tuberculosis infection) within the 
population being studied.53,55 
A biomarker such as interferon-γ could indicate 
M tuberculosis sensitisation (rather than disease) but 
might not, on its own, be adequate to predict active 
tuberculosis disease, especially in countries with a high 
burden and rates of reinfection. Interferon-γ might be 
necessary but not suﬃ  cient on its own for prediction of 
disease. This ﬁ nding is probably true even when 
interferon-γ is regarded as a correlate of protection in 
vaccine studies.59 Interferon-γ alone might not be 
suﬃ  cient as a biomarker because antigen-speciﬁ c 
interferon-γ response is elicited in almost all stages of 
the tuberculosis spectrum.60,61 Therefore, the identiﬁ cation 
of more predictive biomarkers is important, as is 
measurement of an array of biomarkers or incorporation 
of biomarkers with other known risk factors into a 
composite scoring system. For example, age, recent 
infection in young children, recent contact with smear-
positive active case, or HIV infection, in combination 
n/N Person-years Incidence per 1000 person-years 
(95% CI)
Incidence rate ratio 
(95% CI)
The Gambia32*
IGRA+/TST– 4/177 322·6 12·4 (0·3–24·5) 1·29 (0·24–6·93)
IGRA–/TST+ 4/230 416·7 9·6 (0·2–19) 1
IGRA+/TST+ 7/428 790·1 8·86 (2·4–15·4) 2·2 (0·63–7·98)
IGRA–/TST– 6/183 1500 4·0 (0·8–7·2) 1
Turkey27†
IGRA+/TST– 1/44 86 11·7 (0·3–65·1) 1·58 (0·03–30·38)
IGRA–/TST+ 2/213 272 7·4 (0·9–26·6) 1
IGRA+/TST+ 10/337 451 22·2 (10·6–40·8) 5 (1·07–46·93)
IGRA–/TST– 2/314 451 5·1 (0·6–18·4) 1
Senegal37‡
IGRA+/TST– 1/77 170 5·9 (0·83–41·87) 1·19 (0·02–22·94)
IGRA–/TST+ 2/193 406 4·93 (1·23–19·7) 1
IGRA+/TST+ 14/436 950 14·74 (8·73–24·89) 1·50 0·47–6·2)
IGRA–/TST– 4/187 406 9·85 (3·79–26·25) 1
India34*
IGRA+/TST– 1/58 345·6 2·89 (0·4–20·5) 1·1 (0·01–84·97)
IGRA–/TST+ 1/63 374·1 2·67 (0·4–19·0) 1
IGRA+/TST+ 5/217 1280·8 3·9 (1·6–9·4) 1·11 (0·28–4·10)
IGRA–/TST– 7/336 1991·7 3·5 (1·7–7·4) 1
Studies with possible incorporation bias excluded. IGRA=interferon-γ release assay. SFC=spot-forming cells. 
TST=tuberculin skin test. *10 mm TST cutoﬀ , 14 pg/mL IGRA cutoﬀ . †5 mm, 20 SFC ×106. ‡10mm, 32 SFC ×106.
Table 4: Concordance in tuberculin skin test and interferon-γ release assay results and incidence 
of tuberculosis
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with IGRA results, might have much higher predictive 
ability than just interferon-γ response alone. Future 
studies need to assess multivariable risk prediction,54,62 as 
attempted in algorithms such as the Online TST/IGRA 
interpreter,63 and the discriminatory incremental yield of 
new tests to existing clinical algorithms, before predictive 
ability is declared. 
As discussed elsewhere,64 another possible explanation 
for the poor predictive ability of existing tests for latent 
M tuberculosis infection is that a single or cross-sectional 
TST or IGRA result cannot resolve the underlying 
phenotypes because they do not capture information 
about when infection occurred and how the infection 
was fully, partly, or not eliminated by the host. All but two 
studies27,28 included in this review reported results of only 
one IGRA or TST test at baseline. Serial IGRA testing 
might show interesting underlying phenotypes that have 
diﬀ erent histories and trajectories.65 Without serial 
testing, the underlying phenotypes are not distinguishable, 
undermining the predictive value of a single test result.
Our systematic review had limitations. Data included in 
our review did not allow for formal assessment of 
publication bias with methods such as funnel plots or 
regression asymmetry tests. We, therefore, assume some 
degree of publication bias is likely because the number of 
studies of IGRA is rapidly increasing and new studies will 
soon become available—we are aware of at least three 
ongoing studies (in South Africa [NCT00463086],66 
Zambia [ZAMSTAR; ISRCTN36729271 ],67 and the UK44) 
that could not be included. Anecdotal reports exist of 
unpublished negative studies of IGRA—many (about 
50%) IGRA studies have some industry involvement or 
support,5 meaning that studies with negative ﬁ ndings 
might not be published (or publication might be delayed). 
Data used to obtain our main summary measures were 
restricted to low-income to middle-income countries, 
which largely limits interpretation to those settings or 
similar individuals in high-income countries. IGRAs 
might have superior predictive ability in high-income 
settings with low tuberculosis incidence, but we were 
unable to identify this eﬀ ect because of likely incorporation 
or work-up biases. A meta-analysis of individual patient-
data would have allowed for a multivariable assessment 
of discriminatory value and better adjustment of 
confounding, and thus provide a better interpretation of 
available data, but this was not possible. Although 
inclusion of non-commercial IGRAs might be a limitation 
of our analysis, the inclusion of all studies of RD1-based 
assays enabled the most comprehensive synthesis of 
IGRA predictive ability to date.
Further research is needed to identify more predictive 
biomarkers to improve existing tests for latent 
M tuberculosis infection. Indeed, the revised Global Plan 
to Stop TB (2011–15) has set 2015 as the goal for such 
predictive tests.68 Until then, the following strategies 
might be useful to improve the predictive value of existing 
tests: testing only those individuals at high risk of 
tuberculosis; serial testing to identify new infections (ie, 
conversions); incorporation of biomarkers with known 
risk factors (age, recent exposure, HIV infection, etc) into 
risk prediction models; and use of a higher cutoﬀ  for 
prediction of disease (as compared with diagnosis).
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